Glaxo pays 41 million to settle US drug quality matter

Jun 23, 2011

British pharmaceutical giant GlaxoSmithKline said Thursday it is paying 41 million dollars to settle allegations of poor drug quality at a manufacturing plant in Puerto Rico.

The drugmaker did not admit to any at the now shuttered factory, but said it agreed to the settlement "to avoid the expense and uncertainty of protracted litigation and trial," a company statement said.

The payment will be distributed across 37 states and the District of Columbia.

"The company did not admit to any wrongdoing or liability of any kind under these states' consumer protection laws in this settlement," the statement said. At the center of the dispute is a plant in Cidra. A company insider told the US news show 60 Minutes in January that contaminated and poorly dosed medications were being produced there. A federal investigation ensued.

rejected the accusations and said there was no evidence that patients had been harmed.

Federal regulators, the US Department of Justice and the whistelblower Cheryl Eckard's attorney, "all stated there was no indication that patients were harmed as a result of the production issues at Cidra," the company said in response to the CBS report.

GlaxoSmithKline said it closed the plant in 2009 because of "declining demand for the medicines made there."

Before selling the factory in 2010, the drugmaker insisted it "brought it into compliance and to a high level of performance that satisfied both GSK and the FDA ()."

Explore further: Supercomputers link proteins to drug side effects

add to favorites email to friend print save as pdf

Related Stories

FDA warning for hand sanitizer in Puerto Rico

Mar 05, 2010

(AP) -- Puerto Rico's government sent inspectors across the island Thursday to stop stores from selling locally produced hand sanitizers tainted with a dangerous bacteria.

Novo Nordisk pays $26.7 million to settle claims

Jun 11, 2011

Danish drug company Novo Nordisk has agreed to pay $25 million to settle allegations that it promoted the misuse of blood clotting drug NovoSeven, the US Justice Department announced Friday.

Botox maker to pay $600M to resolve investigation

Sep 02, 2010

(AP) -- Allergan Inc., the maker of wrinkle-smoothing Botox, has agreed to pay $600 million to settle a yearslong federal investigation into its marketing of the top-selling, botulin-based drug.

GSK to take $3.4 bln Avandia legal charge

Jan 17, 2011

British drugs firm GlaxoSmithKline said Monday it expects to take a legal charge of £2.2 billion linked to its former blockbuster diabetes product Avandia, sparking a sharp drop in its shares.

Recommended for you

Supercomputers link proteins to drug side effects

2 hours ago

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

9 hours ago

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments : 0